Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.64 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 7/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.39 |
| ▸ | USP8 | P40818 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | FHIT | P49789 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5002478 | 0.89 | CDC7 (0.66) | CDC7MAPKAPK2CYP2A6USP30PIM1 | |
| SCHEMBL5002448 | 0.85 | CDC7 (0.60) | CDC7MAPKAPK2PIM1PIM2FYN | |
| SCHEMBL4991846 | 0.85 | CDC7 (0.60) | CDC7MAPKAPK2PIM1PIM2FYN | |
| SCHEMBL5002677 | 0.85 | CDC7 (0.60) | CDC7MAPKAPK2PIM1PIM2FYN | |
| SCHEMBL4713471 | 0.85 | CDC7 (0.60) | CDC7MAPKAPK2PIM1PIM2FYN | |
| SCHEMBL5000428 | 0.84 | CDC7 (0.62) | CDC7MAPKAPK2PIM1PIM2 | |
| SCHEMBL4994454 | 0.84 | CDC7 (0.65) | CDC7MAPKAPK2PIM1PIM2 | |
| SCHEMBL4996023 | 0.82 | CDC7 (0.57) | CDC7MAPKAPK2PIM1PIM2FYN | |
| SCHEMBL4716033 | 0.82 | CDC7 (0.66) | CDC7MAPKAPK2PIM1PIM2 | |
| SCHEMBL14188405 | 0.82 | CDC7 (0.66) | CDC7MAPKAPK2PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MKNK2, MAPKAPK2, MAP3K2 | CDC7 487/4885MAPKAPK2 2/4885CYP2A6 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.